SHANDONG FOCUSFREDA BIOTECH CO., LTD. – Trademark Portfolio

Entity Type: 22

SHANDONG FOCUSFREDA BIOTECH CO., LTD. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include CHAREO. The owner is based in JINING CITY.

ECONOMIC DEVELOPMENT ZONE, HIGH-SPEED RAILWAY NEW DISTRICT, QUFU CITY

JINING CITY , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BOYO
BOYO
Pending 2024
CHAREO
CHAREO
Registered 2023

Trademark Classifications

SHANDONG FOCUSFREDA BIOTECH CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SHANDONG FOCUSFREDA BIOTECH CO., LTD. have?

SHANDONG FOCUSFREDA BIOTECH CO., LTD. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does SHANDONG FOCUSFREDA BIOTECH CO., LTD. file in?

SHANDONG FOCUSFREDA BIOTECH CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SHANDONG FOCUSFREDA BIOTECH CO., LTD.'s most well-known trademarks?

SHANDONG FOCUSFREDA BIOTECH CO., LTD.'s registered trademark portfolio includes well-known marks such as CHAREO. These are among 1 currently registered trademark in the portfolio.

What is SHANDONG FOCUSFREDA BIOTECH CO., LTD.'s trademark registration success rate?

SHANDONG FOCUSFREDA BIOTECH CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.